berberine has been researched along with Dementia Praecox in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that berberine is a potential weight loss and weight maintenance drug for patients with schizophrenia." | 9.51 | Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. ( Jia, Q; Li, J; Li, M; Liu, Y; Qiu, Y; Zhang, J; Zhang, Y; Zhao, Y, 2022) |
| "The aim of this study was to evaluate the efficacy and safety of berberine as an adjuvant in treating antipsychotic-associated weight gain and metabolic syndrome." | 9.51 | Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. ( Chan, M; Chen, EYH; Feng, Y; Han, F; Lai, WH; Lam, M; Lee, CK; Lee, EHM; Liu, L; Man, SC; Ng, RMK; Qin, Z; Wong, HK; Wong, TL; Zhang, ZJ, 2022) |
| "Previous studies have shown that berberine can improve metabolic disturbances in non-psychiatric patients, but no clinical research has been conducted in schizophrenia." | 9.41 | The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. ( Jia, Q; Li, J; Li, M; Liu, Y; Qiu, Y; Zhang, J; Zhang, Y; Zhao, Y, 2021) |
| "Berberine is an effective drug with anti-inflammatory property, and may be beneficial for the treatment of negative symptoms." | 7.11 | Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. ( Fan, X; Jia, Q; Li, J; Li, M; Liu, Y; Qiu, Y; Zhang, J; Zhang, Y; Zhao, Y, 2022) |
| "This study suggests that berberine is a potential weight loss and weight maintenance drug for patients with schizophrenia." | 5.51 | Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. ( Jia, Q; Li, J; Li, M; Liu, Y; Qiu, Y; Zhang, J; Zhang, Y; Zhao, Y, 2022) |
| "The aim of this study was to evaluate the efficacy and safety of berberine as an adjuvant in treating antipsychotic-associated weight gain and metabolic syndrome." | 5.51 | Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. ( Chan, M; Chen, EYH; Feng, Y; Han, F; Lai, WH; Lam, M; Lee, CK; Lee, EHM; Liu, L; Man, SC; Ng, RMK; Qin, Z; Wong, HK; Wong, TL; Zhang, ZJ, 2022) |
| "Berberine (BBR) is a herbal alkaloid, which shows many neuroprotective properties in neurodegenerative diseases." | 5.51 | Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia. ( Bashiri, H; Ghotbi Ravandi, S; Khodamoradi, M; Nozari, M; Saeedi Goraghani, M; Shabani, M, 2019) |
| "Previous studies have shown that berberine can improve metabolic disturbances in non-psychiatric patients, but no clinical research has been conducted in schizophrenia." | 5.41 | The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. ( Jia, Q; Li, J; Li, M; Liu, Y; Qiu, Y; Zhang, J; Zhang, Y; Zhao, Y, 2021) |
| "(-)Stepholidine (SPD) is an active ingredient of the Chinese herb Stephania intermedia, which binds to the dopamine D(1) and D(2) like receptors." | 5.33 | Effects of (-)stepholidine in animal models for schizophrenia. ( Ellenbroek, BA; Jin, GZ; Zhang, XX, 2006) |
| " In the present study, we examined the potential antipsychotic effect of l-SPD-A in a phencyclidine (PCP)-induced rat model of schizophrenia." | 3.75 | Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand. ( Cai, W; Chen, X; Cheng, J; Guo, Y; Jin, G; Yang, Y; Zhang, H; Zhen, X, 2009) |
| "Berberine is an effective drug with anti-inflammatory property, and may be beneficial for the treatment of negative symptoms." | 3.11 | Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. ( Fan, X; Jia, Q; Li, J; Li, M; Liu, Y; Qiu, Y; Zhang, J; Zhang, Y; Zhao, Y, 2022) |
| "Berberine (BBR) is a herbal alkaloid, which shows many neuroprotective properties in neurodegenerative diseases." | 1.51 | Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia. ( Bashiri, H; Ghotbi Ravandi, S; Khodamoradi, M; Nozari, M; Saeedi Goraghani, M; Shabani, M, 2019) |
| "As berberine is a natural compound that has been safely administered to humans, it opens up new perspectives for the treatment of neuropsychiatric diseases." | 1.34 | The natural product berberine is a human prolyl oligopeptidase inhibitor. ( Giralt, E; Kichik, N; Seguí, J; Tarrago, T, 2007) |
| "(-)Stepholidine (SPD) is an active ingredient of the Chinese herb Stephania intermedia, which binds to the dopamine D(1) and D(2) like receptors." | 1.33 | Effects of (-)stepholidine in animal models for schizophrenia. ( Ellenbroek, BA; Jin, GZ; Zhang, XX, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, Y | 3 |
| Li, M | 3 |
| Zhang, Y | 3 |
| Liu, Y | 3 |
| Zhao, Y | 3 |
| Zhang, J | 3 |
| Jia, Q | 3 |
| Li, J | 3 |
| Chan, M | 1 |
| Qin, Z | 1 |
| Man, SC | 2 |
| Lam, M | 2 |
| Lai, WH | 2 |
| Ng, RMK | 1 |
| Lee, CK | 2 |
| Wong, TL | 1 |
| Lee, EHM | 1 |
| Wong, HK | 2 |
| Feng, Y | 1 |
| Liu, L | 1 |
| Han, F | 1 |
| Chen, EYH | 1 |
| Zhang, ZJ | 2 |
| Fan, X | 1 |
| Chan, MY | 1 |
| Qin, ZS | 1 |
| Ng, MKR | 1 |
| Chen, YHE | 1 |
| Lee, HME | 1 |
| Liu, LY | 1 |
| Gholizadeh, N | 1 |
| Dalimi, A | 1 |
| Ghaffarifar, F | 1 |
| Nader-Mohammadi, M | 1 |
| Molavi, P | 1 |
| Dadkhah, M | 1 |
| Molaei, S | 1 |
| Ghotbi Ravandi, S | 1 |
| Shabani, M | 1 |
| Bashiri, H | 1 |
| Saeedi Goraghani, M | 1 |
| Khodamoradi, M | 1 |
| Nozari, M | 1 |
| Volk, DW | 1 |
| Siegel, BI | 1 |
| Verrico, CD | 1 |
| Lewis, DA | 1 |
| Guo, Y | 1 |
| Zhang, H | 1 |
| Chen, X | 1 |
| Cai, W | 1 |
| Cheng, J | 1 |
| Yang, Y | 1 |
| Jin, G | 1 |
| Zhen, X | 2 |
| Sun, H | 1 |
| Zhu, L | 1 |
| Yang, H | 1 |
| Qian, W | 1 |
| Guo, L | 1 |
| Zhou, S | 1 |
| Gao, B | 1 |
| Li, Z | 1 |
| Zhou, Y | 1 |
| Jiang, H | 1 |
| Chen, K | 1 |
| Liu, H | 1 |
| Ellenbroek, BA | 1 |
| Zhang, XX | 1 |
| Jin, GZ | 2 |
| Tarrago, T | 1 |
| Kichik, N | 1 |
| Seguí, J | 1 |
| Giralt, E | 1 |
| Zhu, ZT | 1 |
| Fu, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Berberine Effects on Clinical Symptoms and Metabolic Disturbance as an Adjunctive Therapy in Patients With Schizophrenia: a Randomized Double-blind Placebo-controlled Study[NCT03548155] | 65 participants (Actual) | Interventional | 2014-07-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for berberine and Dementia Praecox
| Article | Year |
|---|---|
(-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Berberine; Clinical Trials as Topic; Dopamine; Dopamin | 2002 |
4 trials available for berberine and Dementia Praecox
| Article | Year |
|---|---|
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin.
Topics: Adiponectin; Antipsychotic Agents; Berberine; Body Mass Index; Double-Blind Method; Humans; Leptin; | 2022 |
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial.
Topics: Antipsychotic Agents; Berberine; Double-Blind Method; Humans; Metabolic Syndrome; Schizophrenia; Wei | 2022 |
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.
Topics: Antipsychotic Agents; Berberine; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; | 2022 |
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antipsychotic Agents; Berberine; Double-Blind Method; Glycolipids; Humans; Schizophrenia; Treatment | 2021 |
8 other studies available for berberine and Dementia Praecox
| Article | Year |
|---|---|
Berberine for antipsychotic-induced metabolic syndrome in patients with schizophrenia spectrum disorders: abridged secondary publication.
Topics: Antipsychotic Agents; Berberine; Humans; Metabolic Syndrome; Schizophrenia | 2023 |
Berberine improves inhibitory avoidance memory impairment of Toxoplasma gondii-infected rat model of ketamine-induced schizophrenia.
Topics: Animals; Berberine; Brain-Derived Neurotrophic Factor; Ketamine; Rats; Schizophrenia; Toxoplasma | 2023 |
Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia.
Topics: Animals; Animals, Newborn; Berberine; Cognitive Dysfunction; Disease Models, Animal; Dizocilpine Mal | 2019 |
Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.
Topics: Adolescent; Adult; Age Factors; Animals; Antipsychotic Agents; Benzodiazepines; Berberine; Calcium C | 2013 |
Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Berbe | 2009 |
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Topics: Animals; Antipsychotic Agents; Berberine; Berberine Alkaloids; CHO Cells; Cricetinae; Cricetulus; Do | 2013 |
Effects of (-)stepholidine in animal models for schizophrenia.
Topics: Animals; Antipsychotic Agents; Berberine; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; | 2006 |
The natural product berberine is a human prolyl oligopeptidase inhibitor.
Topics: Berberine; Binding Sites; Biological Products; Humans; Magnetic Resonance Spectroscopy; Medicine, Ch | 2007 |